Clinical trials: copd or chronic obstructive
Pulmonary Disease, Chronic Obstructive
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
This is a multicentre, randomized, blinded, double dummy, parallel group study to evaluate the efficacy and safety of UMEC inhalation powder[ (62.5 microgram (mcg) once daily (QD)] when administered via a novel Dry Powder Inhaler…
- Trial name
- NCT02207829
- Testing
- Umeclidinium, Tiotropium
- Where
- 99 sites in United States, Argentina and 11 more
- Volunteers
- 1,017 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Smart Telehealth Exercise Intervention to Reduce COPD Readmissions
This is a prospective randomized controlled study to test the hypothesis that neuromuscular electrical stimulation (NMES) and remote pulmonary rehabilitation at home offered via a smart technology, called Smart TeleHealth…
- Trial name
- NCT03089853
- Testing
- Neuromuscular electrical stimulation (NMES)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Alabama at Birmingham
Chronic Obstructive Pulmonary Disease Moderate
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
This is a phase II, randomised, double blind, placebo controlled, complete block, three way crossover study to investigate treatment with nebulised RPL554 and tiotropium together in patients with moderate to severe chronic…
- Trial name
- NCT03028142
- Testing
- 1.5 mg RPL554 plus tiotropium, 6 mg RPL554 plus tiotropium
- Volunteers
- 30 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Asthma
Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)
This study assesses inhaled corticosteroid plus montelukast compared with inhaled corticosteroid therapy alone for treatment of patients with chronic asthma.
- Trial name
- NCT00666679
- Testing
- Comparator: mometasone, Comparator: montelukast
- Volunteers
- 134 people
- Sponsor
- Organon and Co
Chronic Obstructive Pulmonary Disease - COPD
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
- Trial name
- NCT02796651
- Testing
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Formoterol fumarate (12 μg)
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change
This study evaluates hospitalizations and mortality in patients with Chronic Obstructive Pulmonary Disease (COPD) before and after the implantation of a new COPD treatment plan (replacement of tiotropium soft mist inhaler for…
- Trial name
- NCT06053541
- Where
- Brazil
- Volunteers
- 3,015,000 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice
The objective of this observational study is to collect and evaluate data on medication adherence of patients on maintenance COPD therapy with long-acting anticholinergic (e.g.
- Trial name
- NCT01388166
- Testing
- Education
- Where
- 90 sites in Hungary, Slovakia and 1 more
- Volunteers
- 1,253 people
- Sponsor
- Boehringer Ingelheim
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
This is a prospective, open-label, multicenter Phase 3 study evaluating the performance of the Albuterol Spiromax dose counter in patients with a diagnosis of asthma and/or COPD.
- Trial name
- NCT01857323
- Testing
- Albuterol Spiromax®
- Where
- 30 sites in United States
- Volunteers
- 317 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pulmonary Disease, Chronic Obstructive
Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This multicenter study will be conducted to compare the effect of FF/UMEC/VI with FF/VI plus UMEC on lung function after 24 weeks of treatment.
- Trial name
- NCT02729051
- Testing
- FF/UMEC/VI, FF/VI, UMEC
- Where
- 127 sites in Argentina, Australia and 10 more
- Volunteers
- 1,055 people
- Sponsor
- GlaxoSmithKline
Systemic Juvenile Idiopathic Arthritis
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile…
- Trial name
- NCT02396212
- Testing
- Canakinumab
- Where
- 7 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI).
- Trial name
- NCT02119286
- Testing
- FF, VI, UMEC
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 620 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
AZD8871 is a new chemical entity possessing long-acting effect in a single molecule which presents a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an…
- Trial name
- NCT02814656
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, COPD
Can we Reduce Hospital Attendance Without Compromising Care by the Use of Telephone Consultation
Consultation time in busy respiratory clinics is inevitably limited and attendance is often disruptive to patients' lives; involves time, expense, travel, and waiting; and can have effects upon occupation.
- Conditions
- Asthma, COPD, Sleep Apnea Syndromes, Interstitial Lung Diseases
- Trial name
- NCT00129701
- Testing
- Telephone consultation
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Imperial College London
HIV, Chronic Obstructive Pulmonary Disease (COPD)
Doxycycline for COPD in HIV-Infected Patients
In the context of improved survival from HIV infection itself, chronic obstructive pulmonary disease (COPD); a form of lung disease that includes emphysema, which makes breathing difficult) is emerging as an important cause of…
- Conditions
- HIV, Chronic Obstructive Pulmonary Disease (COPD), Emphysema
- Trial name
- NCT01744093
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study compared the efficacy and safety of NVA237 with tiotropium in patients with moderate to severe COPD. Tiotropium belongs to the same drug class as NVA237.
- Trial name
- GLOW5 (NCT01613326)
- Testing
- NVA237, Tiotropium, salbutamol/albuterol
- Where
- 77 sites in Canada, Croatia and 13 more
- Volunteers
- 657 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Malignancies, Acute Myeloid Leukemia
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic…
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02743351
- Testing
- ProTmune, Control Arm
- Where
- 15 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fate Therapeutics
Pulmonary Disease, Chronic Obstructive
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
This is a randomised study to be conducted in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) to establish whether there is a need for these patients to be continuously treated with an inhaled…
- Trial name
- NCT00975195
- Testing
- tiotropium inhalation, salmeterol xinafoate, fluticasone propionate
- Where
- 222 sites in Australia, Belgium and 21 more
- Volunteers
- 2,488 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3 weeks once daily treatment in Japanese…
- Trial name
- NCT01703845
- Testing
- Tiotropium (high dose) + Olodaterol, Tiotropium (low dose) + Olodaterol
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients
This study evaluates whether individualized dosing schedule of inhaled bronchodilator is more effective than fixed dosing in reducing airway resistance of intubated COPD patients.
- Trial name
- NCT01933984
- Testing
- Bronchodilators inhalation
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Shin-hwar Wu
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD
- Trial name
- NCT02603393
- Testing
- QVA149, Tiotropium, Salmeterol/fluticasone
- Where
- 167 sites in Argentina, Austria and 19 more
- Volunteers
- 1,053 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.